{"id":"gatifloxacin","rwe":[],"_fda":{"id":"8ecbdc67-bc68-4437-b99d-9924e25dfe67","set_id":"1160b16c-929a-4e85-9c0b-1d8c96a7678b","openfda":{"unii":["L4618BD7KJ"],"route":["OPHTHALMIC"],"rxcui":["992395","992399"],"spl_id":["8ecbdc67-bc68-4437-b99d-9924e25dfe67"],"brand_name":["ZYMAXID"],"spl_set_id":["1160b16c-929a-4e85-9c0b-1d8c96a7678b"],"package_ndc":["0023-3615-01","0023-3615-25"],"product_ndc":["0023-3615"],"generic_name":["GATIFLOXACIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["GATIFLOXACIN"],"manufacturer_name":["Allergan, Inc."],"application_number":["NDA022548"],"is_original_packager":[true]},"version":"11","pregnancy":["8.1 Pregnancy Risk Summary There are no available data on the use of ZYMAXID ® in pregnant women to inform a drug-associated risk. Administration of oral gatifloxacin to pregnant rats and rabbits throughout organogenesis did not produce adverse development outcomes at clinically relevant doses. Administration of gatifloxacin to rats during late gestation through lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant doses. Data Animal Data Oral administration of gatifloxacin to pregnant rats throughout organogenesis produced teratogenic effects in rat fetuses, including skeletal/craniofacial malformations, delayed ossification, atrial enlargement, and reduced fetal weight, at doses greater than or equal to 150 mg/kg/day (approximately 600-fold higher than the maximum recommended human ophthalmic dose [MRHOD] for ZYMAXID ® of 0.04 mg/kg/day, on a mg/m 2 basis). No teratogenic effects were observed in rat or rabbit fetuses at doses of gatifloxacin up to 50 mg/kg/day (approximately 200- and 400-fold higher than the MRHOD, respectively, on a mg/m 2 basis). In a perinatal/postnatal study in rats, oral administration of gatifloxacin during late gestation through lactation produced an increase in late gestation fetal loss and neonatal/perinatal mortality at 200 mg/kg/day (approximately 800-fold higher than the MRHOD on a mg/m 2 basis)."],"description":["11 DESCRIPTION ZYMAXID ® is a quinolone antimicrobial topical ophthalmic solution for the treatment of bacterial conjunctivitis. Its chemical name is (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, sesquihydrate. Its molecular formula is C 19 H 22 FN 3 O 4 · 1½ H 2 O and its molecular weight is 402.42. Its chemical structure is: ZYMAXID ® is a clear, pale yellow, sterile, preserved aqueous solution with an osmolality of 260-330 mOsm/kg and a pH of 5.1-5.7. ZYMAXID ® contains the active ingredient gatifloxacin 0.5% (5 mg/mL) and the inactive ingredients benzalkonium chloride 0.005%, edetate disodium, sodium chloride and purified water. ZYMAXID ® may contain hydrochloric acid and/or sodium hydroxide to adjust pH. The chemical structure of ZYMAXID® is a quinolone antimicrobial topical ophthalmic solution for the treatment of bacterial conjunctivitis. Its chemical name is (±)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, sesquihydrate. Its molecular formula is C19H22FN3O4 • 1½ H2O and its molecular weight is 402.42."],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING ZYMAXID ® (gatifloxacin ophthalmic solution) 0.5% is supplied sterile in a white, low density polyethylene (LDPE) bottle with a controlled dropper tip, and a tan, high impact polystyrene (HIPS) cap in the following size: 2.5 mL in 5 mL bottle: NDC 0023-3615-25 Storage: Store at 15°-25°C (59°-77°F). Protect from freezing."],"microbiology":["12.4 Microbiology Gatifloxacin is an 8-methoxyfluoroquinolone with a 3-methylpiperazinyl substituent at C7. The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription, and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. There is no cross-resistance between gatifloxacin and the aforementioned classes of antibiotics. Cross-resistance has been observed between systemic gatifloxacin and some other fluoroquinolones. Resistance to gatifloxacin in vitro develops via multiple-step mutations. Resistance to gatifloxacin in vitro occurs at a general frequency of 1 x 10 -7 to 10 -10 . Gatifloxacin has been shown to be active against most isolates of the following organisms both microbiologically and clinically, in conjunctival infections: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group* Streptococcus oralis * Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections."],"geriatric_use":["8.5 Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of ZYMAXID ® in infants below one year of age have not been established. ZYMAXID ® has been demonstrated in clinical trials to be safe and effective for the treatment of bacterial conjunctivitis in pediatric patients one year or older [ see Clinical Studies ( 14 ) ] ."],"effective_time":"20160901","clinical_studies":["6. 1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. In clinical studies of patients with bacterial conjunctivitis treated with ZYMAXID ® (N=717), the most frequently reported adverse reactions occurring in ≥ 1 % of patients were: worsening of the conjunctivitis, eye irritation, dysgeusia, and eye pain. Additional adverse reactions reported with other formulations of gatifloxacin ophthalmic solution in other clinical studies included chemosis, conjunctival hemorrhage, dry eye, eye discharge, eyelid edema, headache, increased lacrimation, keratitis, red eye, papillary conjunctivitis, and reduced visual acuity.","14 CLINICAL STUDIES In two randomized, double-masked, multicenter clinical trials, where patients 1-89 years of age were dosed for 5 days, ZYMAXID ® was clinically superior to its vehicle on day 6 in patients with conjunctivitis and positive conjunctival cultures. Clinical outcomes for the trials demonstrated clinical success (resolution of conjunctival hyperemia and conjunctival discharge) in 58% (193/333) of patients for the gatifloxacin-treated groups versus 45% (148/325) for the vehicle-treated groups. Microbiological outcomes for the same clinical trials demonstrated a statistically superior eradication rate for causative pathogens of 90% (301/333) for gatifloxacin vs. 70% (228/325) for vehicle. Please note that microbiological eradication does not always correlate with clinical outcome in anti-infective trials."],"pharmacokinetics":["12.3 Pharmacokinetics Gatifloxacin ophthalmic solution 0.5% was administered to one eye of 6 healthy male subjects each in an escalated dosing regimen starting with a single 2 drop dose, then 2 drops 4 times daily for 7 days, and finally 2 drops 8 times daily for 3 days. At all time points, serum gatifloxacin levels were below the lower limit of quantification (5 ng/mL) in all subjects."],"adverse_reactions":["6 ADVERSE REACTIONS The following serious adverse reactions are described elsewhere in the labeling: Hypersensitivity [ see Contraindications ( 4 ) and Warnings and Precautions ( 5.1 ) ] Growth of Resistant Organisms With Prolonged Use [ see Warnings and Precautions ( 5.2 ) ] Corneal Endothelial Cell Injury [ see Warnings and Precautions ( 5.3 ) ] Most common adverse reactions occurring in ≥ 1 % of patients included worsening of conjunctivitis, eye irritation, dysgeusia, and eye pain. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Allergan at 1-800-433-8871 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6. 1 Clinical Studies Experience Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice. In clinical studies of patients with bacterial conjunctivitis treated with ZYMAXID ® (N=717), the most frequently reported adverse reactions occurring in ≥ 1 % of patients were: worsening of the conjunctivitis, eye irritation, dysgeusia, and eye pain. Additional adverse reactions reported with other formulations of gatifloxacin ophthalmic solution in other clinical studies included chemosis, conjunctival hemorrhage, dry eye, eye discharge, eyelid edema, headache, increased lacrimation, keratitis, red eye, papillary conjunctivitis, and reduced visual acuity. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of ZYMAXID ® or with other formulations of gatifloxacin ophthalmic solution. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These reactions included anaphylactic reactions and angioedema (including pharyngeal, oral or facial edema), blepharitis, dyspnea, eye pruritus, eye swelling (including corneal and conjunctival edema), hypersensitivity, including signs and symptoms of eye allergy and allergic dermatitis, nausea, pruritus (including pruritus generalized, rash, urticaria), and vision blurred."],"contraindications":["4 CONTRAINDICATIONS ZYMAXID ® is contraindicated in patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medication [see Warnings and Precautions ( 5.1 )] . ZYMAXID ® is contraindicated in patients with a history of hypersensitivity to gatifloxacin, to other quinolones, or to any of the components in this medication. ( 4 )"],"mechanism_of_action":["12.1 Mechanism of Action Gatifloxacin is a quinolone antimicrobial [ see Microbiology ( 12.4 ) ] ."],"recent_major_changes":["Contraindications, Hypersensitivity ( 4 ) 09/2016 Warnings and Precautions, Hypersensitivity ( 5.1 ) 09/2016"],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Gatifloxacin is a quinolone antimicrobial [ see Microbiology ( 12.4 ) ] . 12.3 Pharmacokinetics Gatifloxacin ophthalmic solution 0.5% was administered to one eye of 6 healthy male subjects each in an escalated dosing regimen starting with a single 2 drop dose, then 2 drops 4 times daily for 7 days, and finally 2 drops 8 times daily for 3 days. At all time points, serum gatifloxacin levels were below the lower limit of quantification (5 ng/mL) in all subjects. 12.4 Microbiology Gatifloxacin is an 8-methoxyfluoroquinolone with a 3-methylpiperazinyl substituent at C7. The antibacterial action of gatifloxacin results from inhibition of DNA gyrase and topoisomerase IV. DNA gyrase is an essential enzyme that is involved in the replication, transcription, and repair of bacterial DNA. Topoisomerase IV is an enzyme known to play a key role in the partitioning of the chromosomal DNA during bacterial cell division. The mechanism of action of fluoroquinolones including gatifloxacin is different from that of aminoglycoside, macrolide, and tetracycline antibiotics. Therefore, gatifloxacin may be active against pathogens that are resistant to these antibiotics and these antibiotics may be active against pathogens that are resistant to gatifloxacin. There is no cross-resistance between gatifloxacin and the aforementioned classes of antibiotics. Cross-resistance has been observed between systemic gatifloxacin and some other fluoroquinolones. Resistance to gatifloxacin in vitro develops via multiple-step mutations. Resistance to gatifloxacin in vitro occurs at a general frequency of 1 x 10 -7 to 10 -10 . Gatifloxacin has been shown to be active against most isolates of the following organisms both microbiologically and clinically, in conjunctival infections: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group* Streptococcus oralis * Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections."],"indications_and_usage":["1 INDICATIONS AND USAGE ZYMAXID ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Aerobic gram-positive bacteria: Staphylococcus aureus Staphylococcus epidermidis Streptococcus mitis group * Streptococcus oralis * Streptococcus pneumoniae Aerobic gram-negative bacteria: Haemophilus influenzae *Efficacy for these organisms were studied in fewer than 10 infections . ZYMAXID ® is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible strains of the following organisms: Haemophilus influenzae, Staphylococcus aureus, Staphylococcus epidermidis, Streptococcus mitis group , Streptococcus oralis, Streptococcus pneumoniae ( 1 )"],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Hypersensitivity ( 5.1 ) Growth of Resistant Organisms with Prolonged Use ( 5.2 ) Corneal Endothelial Cell Injury ( 5.3 ) 5.1 Hypersensitivity Some patients receiving topical ophthalmic gatifloxacin experienced hypersensitivity reactions including anaphylactic reactions, angioedema (including pharyngeal, laryngeal, or facial edema), dyspnea, urticaria, and itching, even following a single dose. Rare cases of Stevens-Johnson Syndrome were reported in association with topical ophthalmic gatifloxacin use. If an allergic reaction to gatifloxacin occurs, discontinue the drug [see Patient Counseling Information ( 17 )] . 5.2 Growth of Resistant Organisms with Prolonged Use Prolonged use of ZYMAXID ® may result in overgrowth of nonsusceptible organisms, including fungi. If superinfection occurs, discontinue use and institute alternative therapy. Whenever clinical judgment dictates, examine the patient with the aid of magnification, such as slit lamp biomicroscopy and where appropriate, fluorescein staining. 5. 3 Corneal Endothelial Cell Injury ZYMAXID ® is for topical ophthalmic use. ZYMAXID ® may cause corneal endothelial cell injury if introduced directly into the anterior chamber of the eye."],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis There was no increase in neoplasms among B6C3F1 mice given gatifloxacin in the diet for 18 months at doses averaging 81 mg/kg/day in males and 90 mg/kg/day in females. These doses are approximately 175-fold higher than the maximum recommended ophthalmic dose (MRHOD) of 0.04 mg/kg/day ZYMAXID ® in a 60 kg human (on a mg/m 2 basis). A statistically significant increase in the incidence of large granular lymphocyte (LGL) leukemia was seen in male rats treated with 100 mg/kg/day (approximately 405-fold higher than the MRHOD, on a mg/m 2 basis). Fischer 344 rats have a high spontaneous background rate of LGL leukemia and the incidence in high-dose males only slightly exceeded the historical control range established for this strain. There was no increase in neoplasms among Fischer 344 rats given gatifloxacin in the diet for 2 years at doses averaging 47 mg/kg/day in males and 139 mg/kg/day in females (approximately 190- and 560-fold higher than the MRHOD, respectively), on a mg/m 2 basis. Mutagenesis In genetic toxicity tests, gatifloxacin was positive in 1 of 5 strains used in bacterial reverse mutation assays: Salmonella strain TA102. Gatifloxacin was positive in in vitro mammalian cell mutation and chromosome aberration assays. Gatifloxacin was positive in in vitro unscheduled DNA synthesis in rat hepatocytes but not human leukocytes. Gatifloxacin was negative in in vivo micronucleus tests in mice, cytogenetics test in rats, and DNA repair test in rats. The genotoxic findings are similar to findings obtained with other quinolones and may be due to the pharmacologic inhibitory effects of high concentrations of gatifloxacin on eukaryotic type II DNA topoisomerase. Impairment of Fertility Oral administration of gatifloxacin produced no adverse effects on fertility or reproduction in rats at doses up to 200 mg/kg/day (approximately 800-fold higher than the MRHOD, on a mg/m 2 basis)."],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Avoiding Contamination of the Product Instruct patients to avoid contaminating the applicator tip with material from the eye, fingers, or other source. Potential for Hypersensitivity Reactions Advise patients to discontinue use immediately and contact the physician at the first sign of a rash or hypersensitivity reaction [see Warnings and Precautions ( 5.1 ) and Contraindication ( 4 ) ] . © 2017 Allergan. All rights reserved. All trademarks are the property of their respective owners. Patented. See www.allergan.com/patents Irvine, CA 92612 Made in the U.S.A. 72366US14"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Day 1: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times. Day 2 through Day 7: Instill one drop two to four times daily in the affected eye(s) while awake. Day 1: Instill one drop every two hours in the affected eye(s) while awake, up to 8 times on Day 1. Days 2 through 7: Instill one drop two to four times daily in the affected eye(s) while awake on Days 2 through 7. ( 2 )"],"spl_product_data_elements":["ZYMAXID gatifloxacin GATIFLOXACIN GATIFLOXACIN ANHYDROUS EDETATE DISODIUM WATER SODIUM CHLORIDE BENZALKONIUM CHLORIDE HYDROCHLORIC ACID SODIUM HYDROXIDE"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Ophthalmic solution: 0.5% gatifloxacin (5 mg/mL) Ophthalmic solution: 0.5% gatifloxacin (5mg/mL) ( 3 )"],"recent_major_changes_table":["<table><col width=\"331\"/><col width=\"114\"/><tbody><tr><td>Contraindications, Hypersensitivity (<linkHtml href=\"#_4_CONTRAINDICATIONS\">4</linkHtml>)</td><td>09/2016</td></tr><tr><td>Warnings and Precautions, Hypersensitivity (<linkHtml href=\"#_5_1__\">5.1</linkHtml>)</td><td>09/2016</td></tr></tbody></table>"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no available data on the use of ZYMAXID ® in pregnant women to inform a drug-associated risk. Administration of oral gatifloxacin to pregnant rats and rabbits throughout organogenesis did not produce adverse development outcomes at clinically relevant doses. Administration of gatifloxacin to rats during late gestation through lactation did not produce adverse maternal, fetal or neonatal effects at clinically relevant doses. Data Animal Data Oral administration of gatifloxacin to pregnant rats throughout organogenesis produced teratogenic effects in rat fetuses, including skeletal/craniofacial malformations, delayed ossification, atrial enlargement, and reduced fetal weight, at doses greater than or equal to 150 mg/kg/day (approximately 600-fold higher than the maximum recommended human ophthalmic dose [MRHOD] for ZYMAXID ® of 0.04 mg/kg/day, on a mg/m 2 basis). No teratogenic effects were observed in rat or rabbit fetuses at doses of gatifloxacin up to 50 mg/kg/day (approximately 200- and 400-fold higher than the MRHOD, respectively, on a mg/m 2 basis). In a perinatal/postnatal study in rats, oral administration of gatifloxacin during late gestation through lactation produced an increase in late gestation fetal loss and neonatal/perinatal mortality at 200 mg/kg/day (approximately 800-fold higher than the MRHOD on a mg/m 2 basis). 8.2 Lactation Risk Summary There is no information regarding the presence of ZYMAXID ® in human milk, the effect of gatifloxacin on breastfed infants, or the effect of gatifloxacin on milk production. Gatifloxacin was found in the breast milk of rats following oral administration of gatifloxacin during lactation. However, systemic levels of gatifloxacin following topical ocular administration are low [see Clinical Pharmacology ( 12.3 ) ], and it is not known whether gatifloxacin would be present in maternal milk at measurable levels following topical ocular administration. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for ZYMAXID ® and any potential adverse effects on the breastfed child from ZYMAXID ® . 8.4 Pediatric Use The safety and effectiveness of ZYMAXID ® in infants below one year of age have not been established. ZYMAXID ® has been demonstrated in clinical trials to be safe and effective for the treatment of bacterial conjunctivitis in pediatric patients one year or older [ see Clinical Studies ( 14 ) ] . 8.5 Geriatric Use No overall differences in safety or effectiveness have been observed between elderly and younger patients."],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL NDC 0023-3615-25 ZYMAXID (gatifloxacin ophthalmic solution) 0.5% 2.5 mL Rx Only Sterile PRINCIPAL DISPLAY PANEL NDC 0023-3615-25 ZYMAXID (gatifloxacin ophthalmic solution) 0.5% 2.5 mL Rx Only Sterile"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenesis There was no increase in neoplasms among B6C3F1 mice given gatifloxacin in the diet for 18 months at doses averaging 81 mg/kg/day in males and 90 mg/kg/day in females. These doses are approximately 175-fold higher than the maximum recommended ophthalmic dose (MRHOD) of 0.04 mg/kg/day ZYMAXID ® in a 60 kg human (on a mg/m 2 basis). A statistically significant increase in the incidence of large granular lymphocyte (LGL) leukemia was seen in male rats treated with 100 mg/kg/day (approximately 405-fold higher than the MRHOD, on a mg/m 2 basis). Fischer 344 rats have a high spontaneous background rate of LGL leukemia and the incidence in high-dose males only slightly exceeded the historical control range established for this strain. There was no increase in neoplasms among Fischer 344 rats given gatifloxacin in the diet for 2 years at doses averaging 47 mg/kg/day in males and 139 mg/kg/day in females (approximately 190- and 560-fold higher than the MRHOD, respectively), on a mg/m 2 basis. Mutagenesis In genetic toxicity tests, gatifloxacin was positive in 1 of 5 strains used in bacterial reverse mutation assays: Salmonella strain TA102. Gatifloxacin was positive in in vitro mammalian cell mutation and chromosome aberration assays. Gatifloxacin was positive in in vitro unscheduled DNA synthesis in rat hepatocytes but not human leukocytes. Gatifloxacin was negative in in vivo micronucleus tests in mice, cytogenetics test in rats, and DNA repair test in rats. The genotoxic findings are similar to findings obtained with other quinolones and may be due to the pharmacologic inhibitory effects of high concentrations of gatifloxacin on eukaryotic type II DNA topoisomerase. Impairment of Fertility Oral administration of gatifloxacin produced no adverse effects on fertility or reproduction in rats at doses up to 200 mg/kg/day (approximately 800-fold higher than the MRHOD, on a mg/m 2 basis)."]},"tags":[],"safety":{"boxedWarnings":[],"commonSideEffects":[{"effect":"Worsening of conjunctivitis","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Eye irritation","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Dysgeusia","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Eye pain","drugRate":"","severity":"serious","_validated":false,"_confidence":0.3},{"effect":"Chemosis","drugRate":"reported","severity":"unknown"},{"effect":"Conjunctival hemorrhage","drugRate":"reported","severity":"unknown"},{"effect":"Dry eye","drugRate":"reported","severity":"unknown"},{"effect":"Eye discharge","drugRate":"reported","severity":"unknown"},{"effect":"Eyelid edema","drugRate":"reported","severity":"unknown"},{"effect":"Headache","drugRate":"reported","severity":"unknown"},{"effect":"Increased lacrimation","drugRate":"reported","severity":"unknown"},{"effect":"Keratitis","drugRate":"reported","severity":"unknown"},{"effect":"Red eye","drugRate":"reported","severity":"unknown"},{"effect":"Papillary conjunctivitis","drugRate":"reported","severity":"unknown"},{"effect":"Reduced visual acuity","drugRate":"reported","severity":"unknown"},{"effect":"Anaphylactic reactions","drugRate":"reported","severity":"unknown"},{"effect":"Angioedema","drugRate":"reported","severity":"unknown"},{"effect":"Blepharitis","drugRate":"reported","severity":"unknown"},{"effect":"Dyspnea","drugRate":"reported","severity":"unknown"},{"effect":"Eye pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Eye swelling","drugRate":"reported","severity":"unknown"},{"effect":"Hypersensitivity","drugRate":"reported","severity":"unknown"},{"effect":"Nausea","drugRate":"reported","severity":"unknown"},{"effect":"Pruritus","drugRate":"reported","severity":"unknown"},{"effect":"Rash","drugRate":"reported","severity":"unknown"},{"effect":"Urticaria","drugRate":"reported","severity":"unknown"},{"effect":"Vision blurred","drugRate":"reported","severity":"unknown"}]},"trials":[],"_chembl":null,"aliases":[],"patents":[],"pricing":[{"market":"United States","source":"CMS National Average Drug Acquisition Cost (NADAC)","asOfDate":"2024-01-03","unitCost":"$11.6847/ML","priceType":"NADAC","sourceUrl":"https://data.medicaid.gov/dataset/4j6z-xnwq","annualCost":"$4,206","description":"GATIFLOXACIN 0.5% EYE DROPS","retrievedDate":"2026-04-07"}],"_fixedAt":"2026-03-30T14:19:56.537241","_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=GATIFLOXACIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T02:34:08.498299+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T02:34:14.847608+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=GATIFLOXACIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T02:34:15.347061+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:34:07.394916+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:34:07.394945+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Topoisomerase IV inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:34:16.436858+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL31/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T02:34:16.105133+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA022548","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T02:34:07.394950+00:00"}},"allNames":"zymar","offLabel":[],"timeline":[],"_dailymed":{"setId":"2dc44fc5-b7fc-40ec-8e9b-d86fae1fc523","title":"GATIFLOXACIN OPHTHALMIC SOLUTION 0.5% SOLUTION [CAPLIN STERILES LIMITED]"},"ecosystem":[],"mechanism":{"target":"DNA gyrase, DNA gyrase, DNA gyrase subunit A","modality":"Small Molecule","_target_confidence":0.5},"_scrapedAt":"2026-03-28T00:33:10.611Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"references":[],"_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:34:21.616829+00:00","fieldsConflicting":5,"overallConfidence":0.8},"biosimilars":[],"competitors":[],"dataSources":[{"url":"https://data.medicaid.gov/dataset/4j6z-xnwq","name":"CMS National Average Drug Acquisition Cost (NADAC)","fields":["pricing"],"retrievedDate":"2026-04-07"}],"indications":{"approved":[{"name":"Acute bacterial sinusitis","diseaseId":"acute-bacterial-sinusitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute exacerbation of chronic bronchitis","diseaseId":"acute-exacerbation-of-chronic-bronchitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute gonococcal cervicitis","diseaseId":"acute-gonococcal-cervicitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Acute gonococcal urethritis","diseaseId":"acute-gonococcal-urethritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial conjunctivitis","diseaseId":"bacterial-conjunctivitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial pneumonia","diseaseId":"bacterial-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Bacterial urinary infection","diseaseId":"bacterial-urinary-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Chlamydial pneumonia","diseaseId":"chlamydial-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Complicated Proteus UTI","diseaseId":"complicated-proteus-uti","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"E. Coli Pyelonephritis","diseaseId":"e.-coli-pyelonephritis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Escherichia coli urinary tract infection","diseaseId":"escherichia-coli-urinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Gonorrhea of rectum","diseaseId":"gonorrhea-of-rectum","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Haemophilus Influenzae Chronic Bronchitis","diseaseId":"haemophilus-influenzae-chronic-bronchitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Haemophilus Parainfluenzae Chronic Bronchitis","diseaseId":"haemophilus-parainfluenzae-chronic-bronchitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Haemophilus Parainfluenzae Pneumonia","diseaseId":"haemophilus-parainfluenzae-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Haemophilus influenzae pneumonia","diseaseId":"haemophilus-influenzae-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Infection due to Staphylococcus aureus","diseaseId":"infection-due-to-staphylococcus-aureus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Klebsiella cystitis","diseaseId":"klebsiella-cystitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Legionella Pneumophila Pneumonia","diseaseId":"legionella-pneumophila-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Moraxella Catarrhalis Chronic Bronchitis","diseaseId":"moraxella-catarrhalis-chronic-bronchitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Moraxella Catarrhalis Pneumonia","diseaseId":"moraxella-catarrhalis-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumococcal pneumonia","diseaseId":"pneumococcal-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Mycoplasma pneumoniae","diseaseId":"pneumonia-due-to-mycoplasma-pneumoniae","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Pneumonia due to Streptococcus","diseaseId":"pneumonia-due-to-streptococcus","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Proteus urinary tract infection","diseaseId":"proteus-urinary-tract-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Skin and Skin Structure Streptococcus Infection","diseaseId":"skin-and-skin-structure-streptococcus-infection","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcal pneumonia","diseaseId":"staphylococcal-pneumonia","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Staphylococcus Chronic Bronchitis","diseaseId":"staphylococcus-chronic-bronchitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Streptococcus Pneumoniae Chronic Bronchitis","diseaseId":"streptococcus-pneumoniae-chronic-bronchitis","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"},{"name":"Urinary tract infection caused by Klebsiella","diseaseId":"urinary-tract-infection-caused-by-klebsiella","approvalDate":"","lineOfTherapy":"","approvalCountry":"United States"}],"offLabel":[],"pipeline":[]},"_fixedFields":["sideEffects","generics(6)","patents(0)","modality→Small Molecule"],"labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[],"trialDetails":[{"nctId":"NCT03479736","phase":"","title":"A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2017-11-20","conditions":"Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting","enrollment":117911},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":"Tuberculosis, Multidrug-Resistant","enrollment":205},{"nctId":"NCT05771194","phase":"PHASE4","title":"Analysis of Postoperative Ocular Surface Changes and Intervention Effect After PPV in MGD Dry Eye Patients","status":"COMPLETED","sponsor":"Tianjin Medical University Eye Hospital","startDate":"2021-02-01","conditions":"Meibomian Gland Dysfunction of Unspecified Eye, Unspecified Eyelid","enrollment":40},{"nctId":"NCT03578276","phase":"PHASE4","title":"Prophylactic Treatment: Lessdrops™ vs Standard Drops Regimen","status":"COMPLETED","sponsor":"Carolina Eyecare Physicians, LLC","startDate":"2018-06-22","conditions":"Cataract","enrollment":35},{"nctId":"NCT03696342","phase":"PHASE3","title":"Efficacy of the Ophthalmic Pazufloxacin 0.6% for Bacterial Conjunctivitis, Compared to Gatifloxacin 0.3%.","status":"TERMINATED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2018-10-01","conditions":"Conjunctivitis, Bacterial","enrollment":46},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":"Osteomyelitis","enrollment":11},{"nctId":"NCT02717871","phase":"PHASE3","title":"Swiss PACK-CXL Multicenter Trial for the Treatment of Infectious Keratitis","status":"COMPLETED","sponsor":"University Hospital, Geneva","startDate":"2016-03","conditions":"Keratitis; Infectious Disease (Manifestation)","enrollment":35},{"nctId":"NCT02980523","phase":"PHASE2","title":"Safety and Efficacy of PRO-157 vs Moxifloxacin vs Gatifloxacin in Patients With Bacterial Conjunctivitis (Pazufloxacin)","status":"COMPLETED","sponsor":"Laboratorios Sophia S.A de C.V.","startDate":"2015-03","conditions":"Bacterial Conjunctivitis","enrollment":150},{"nctId":"NCT00518089","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2008-02","conditions":"Bacterial Conjunctivitis","enrollment":859},{"nctId":"NCT00396084","phase":"PHASE1, PHASE2","title":"Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2004-02-10","conditions":"Tuberculosis","enrollment":70},{"nctId":"NCT03625739","phase":"","title":"Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2018-07-01","conditions":"Tuberculosis","enrollment":800},{"nctId":"NCT00335231","phase":"NA","title":"Preoperative Topical Gatifloxacin on Anterior Chamber Cultures After Cataract Surgery","status":"WITHDRAWN","sponsor":"Queen's University","startDate":"2006-06","conditions":"Endophthalmitis","enrollment":""},{"nctId":"NCT01218737","phase":"PHASE3","title":"Non-Inferiority of Gatifloxacin/Prednisolone Association vs Isolated Administration in Prevention of Ocular Infection/Inflammation","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2009-01","conditions":"Ocular Infection and Inflammation","enrollment":101},{"nctId":"NCT00410891","phase":"PHASE4","title":"Topical Antibiotics and Intravitreous Injections","status":"COMPLETED","sponsor":"Stanford University","startDate":"2008-07","conditions":"Intravitreous, Injections","enrollment":129},{"nctId":"NCT02943967","phase":"NA","title":"Corneal Cross-linking and Refractive Surface Ablation in Patients With Asymmetric Corneas","status":"COMPLETED","sponsor":"Federal University of São Paulo","startDate":"2010-01","conditions":"Surgical Procedure, Unspecified","enrollment":44},{"nctId":"NCT01421693","phase":"PHASE4","title":"Gatifloxacin Versus Ceftriaxone in the Treatment of Enteric Fever","status":"COMPLETED","sponsor":"Oxford University Clinical Research Unit, Vietnam","startDate":"2011-09","conditions":"Enteric Fever, Typhoid Fever","enrollment":300},{"nctId":"NCT00831961","phase":"","title":"Antibiotic Resistant Patterns of Conjunctival and Nasophayngeal Flora After Repeated Exposure to Topical Antibiotics","status":"COMPLETED","sponsor":"Vanderbilt University","startDate":"2009-01","conditions":"Age-related Macular Degeneration","enrollment":24},{"nctId":"NCT01928693","phase":"PHASE2","title":"A Comparison of Three Fluoroquinolone Topical Eyedrops in the Treatment of Infectious Corneal Ulcers.","status":"TERMINATED","sponsor":"Cornea Consultants Of Nashville","startDate":"2013-07","conditions":"Corneal Ulcers","enrollment":2},{"nctId":"NCT00350363","phase":"PHASE4","title":"One Hour Preoperative Gatifloxacin","status":"COMPLETED","sponsor":"Stanford University","startDate":"2007-01","conditions":"Ophthalmic Surgery","enrollment":60},{"nctId":"NCT01330355","phase":"PHASE3","title":"Besifloxacin Ophthalmic Suspension Verses Gatifloxacin Ophthalmic Solution in Neonates With Bacterial Conjunctivitis","status":"TERMINATED","sponsor":"Bausch & Lomb Incorporated","startDate":"2011-05","conditions":"Bacterial Conjunctivitis","enrollment":33},{"nctId":"NCT02196740","phase":"NA","title":"Research of the Application of Triple Antibiotic Paste in Primary Teeth With Pericpical Periodontitis","status":"UNKNOWN","sponsor":"Lin Jiacheng","startDate":"2013-06","conditions":"Periapical Diseases","enrollment":100},{"nctId":"NCT00414011","phase":"NA","title":"Comparison of the Effect of 4th Generation Fluoroquinolones, Gatifloxacin and Moxifloxacin, on Epithelial Healing Following Photorefractive Keratectomy (PRK), A Substudy of: Initial Evaluation of Excimer Laser Keratorefractive Surgery in U.S. Army Personnel (WU # 2335-99)","status":"COMPLETED","sponsor":"Walter Reed Army Medical Center","startDate":"","conditions":"Epithelium, Corneal","enrollment":40},{"nctId":"NCT01881438","phase":"","title":"An Observational Study of Oral Fluoroquinolones and the Risk of Retinal Detachment","status":"COMPLETED","sponsor":"Janssen Research & Development, LLC","startDate":"2000-01","conditions":"Retinal Detachment","enrollment":119924},{"nctId":"NCT00466570","phase":"NA","title":"Prospective Randomized Comparison of Zymar(Gatifloxacin) and Vigamox (Moxifloxacin) in Killing Conjunctival Bacterial Flora Following a One-hour Application","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2007-04","conditions":"Conjunctical Flora","enrollment":""},{"nctId":"NCT00874887","phase":"PHASE4","title":"A Clinical Study to Evaluate if Benzalkonium Chloride (BAK) in a Quinolone Eyedrop Reduces the Likelihood of Developing Resistant Organisms","status":"COMPLETED","sponsor":"Allergan","startDate":"2009-03","conditions":"Anti-biotic Resistance","enrollment":66},{"nctId":"NCT00824070","phase":"PHASE1","title":"Assessment of the Concentrations of Besifloxacin, Moxifloxacin, or Gatifloxacin in the Aqueous Humor of Subjects","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-02","conditions":"Cataract Extraction","enrollment":105},{"nctId":"NCT00905762","phase":"PHASE1","title":"Concentration of Besifloxacin, Gatifloxacin, and Moxifloxacin in Human Conjunctiva After Topical Instillation","status":"COMPLETED","sponsor":"Bausch & Lomb Incorporated","startDate":"2009-03","conditions":"Healthy","enrollment":119},{"nctId":"NCT00509873","phase":"PHASE3","title":"A Study of the Safety and Efficacy of Gatifloxacin in Patients With Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-08","conditions":"Bacterial Conjunctivitis","enrollment":578},{"nctId":"NCT00464438","phase":"PHASE4","title":"A Study to Evaluate the Safety and Efficacy of Gatifloxacin for the Treatment of Bacterial Conjunctivitis","status":"COMPLETED","sponsor":"Allergan","startDate":"2007-06","conditions":"Bacterial Conjunctivitis","enrollment":171},{"nctId":"NCT00892918","phase":"NA","title":"Effect of Moxifloxacin Versus Gatifloxacin on Corneal Epithelium Following Pterygium Excision","status":"UNKNOWN","sponsor":"Meir Medical Center","startDate":"2009-06","conditions":"Primary Pterygium","enrollment":40},{"nctId":"NCT00703313","phase":"PHASE4","title":"Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators","status":"COMPLETED","sponsor":"Santen Inc.","startDate":"2008-05","conditions":"Healthy","enrollment":72},{"nctId":"NCT00651586","phase":"PHASE2","title":"Safety and Efficacy Study of Gatifloxacin Compared With Ciprofloxacin in Patients With Acute Bacterial Corneal Ulcers","status":"COMPLETED","sponsor":"Allergan","startDate":"2003-10","conditions":"Acute Bacterial Corneal Ulcers, Bacterial Keratitis","enrollment":129},{"nctId":"NCT00620997","phase":"PHASE1","title":"Proparacaine vs Placebo for Corneal Injuries","status":"COMPLETED","sponsor":"London Health Sciences Centre","startDate":"2005-10","conditions":"Corneal Abrasions","enrollment":43},{"nctId":"NCT00569881","phase":"","title":"Effect of Topical Fluoroquinolones on Epithelial Wound Healing After PRK","status":"COMPLETED","sponsor":"Donnenfeld, Eric, M.D.","startDate":"2007-01","conditions":"Corneal Epithelial Wound Healing","enrollment":22},{"nctId":"NCT00433225","phase":"PHASE4","title":"Efficacy of Topical Ketorolac Versus Placebo for Improving Visual Outcomes Following Multifocal IOL Implantation","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":"Macula Thickening","enrollment":""},{"nctId":"NCT00407017","phase":"PHASE4","title":"Therapeutic Variables in Cataract Surgery","status":"COMPLETED","sponsor":"Innovative Medical","startDate":"","conditions":"Cataract Surgery","enrollment":""},{"nctId":"NCT00478764","phase":"NA","title":"Intraocular Steroid After Cataract Surgery Study","status":"COMPLETED","sponsor":"Dean Health System","startDate":"2006-03","conditions":"Cataract","enrollment":41},{"nctId":"NCT00347828","phase":"PHASE4","title":"Effectiveness Study of Zymar Versus Vigamox for Preoperative Sterilization of the Ocular Surface After Loading Dose","status":"UNKNOWN","sponsor":"Ophthalmic Consultants of Boston","startDate":"2006-06","conditions":"Eye Infection, Infection","enrollment":40},{"nctId":"NCT00216385","phase":"PHASE3","title":"A Controlled Trial of a 4-Month Quinolone-Containing Regimen for the Treatment of Pulmonary Tuberculosis","status":"UNKNOWN","sponsor":"Institut de Recherche pour le Developpement","startDate":"2005-01","conditions":"Tuberculosis","enrollment":2070}],"_emaApprovals":[],"_faersSignals":[{"count":157,"reaction":"HYPOGLYCAEMIA"},{"count":104,"reaction":"HYPERGLYCAEMIA"},{"count":70,"reaction":"ANAPHYLACTIC REACTION"},{"count":70,"reaction":"DIARRHOEA"},{"count":68,"reaction":"DRUG INTOLERANCE"},{"count":59,"reaction":"RASH"},{"count":58,"reaction":"DIZZINESS"},{"count":55,"reaction":"DYSPNOEA"},{"count":52,"reaction":"EYE PAIN"},{"count":50,"reaction":"NAUSEA"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Ophthalmic"},"_patentsChecked":true,"crossReferences":{"chemblId":"CHEMBL31"},"formularyStatus":[],"_approvalHistory":[],"developmentCodes":[],"ownershipHistory":[],"publicationCount":1847,"therapeuticAreas":["Infectious Disease"],"biosimilarFilings":[],"companionDiagnostics":[],"genericManufacturers":6,"_genericFilersChecked":true,"genericManufacturerList":["Apotex Inc","Caplin","Hikma","Lupin Ltd","Rising","Sandoz"],"phase":"marketed","status":"withdrawn","brandName":"Zymar","genericName":"GATIFLOXACIN","companyName":"Allergan","companyId":"","modality":"Small molecule","firstApprovalDate":"2003","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T02:34:21.616829+00:00","fieldsConflicting":5,"overallConfidence":0.8},"verificationStatus":"verified","dataCompleteness":{"mechanism":false,"indications":true,"safety":true,"trials":true,"score":3}}